In this study, the fibronectin–ILT3 interaction is shown to represent a “stromal checkpoint” through which the extracellular matrix actively suppresses tumor-associated myeloid cells. Therapeutics ...

2018 Meetings Abstracts: Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic January 8–11, 2018; San Diego, CA Proceedings: AACR Annual ...

AbstractPurpose:. This research investigates the association between benzodiazepines (BZD) and cancer patient survival outcomes, the pancreatic cancer tumor microenvironment, and cancer-associated ...

AACR Project GENIE has now accrued data from >110,000 tumors, placing it among the largest repository of publicly available, clinically annotated genomic data in the world. GENIE has emerged as a ...

Integrating spatial transcriptomics, pseudotime, and machine learning analyses is effective for identifying prostate cancer biomarkers that are reliable in different settings and measurable with ...

Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent ...

The preclinical profile of STX-478, a mutant-selective, allosteric PI3Kα inhibitor, demonstrates its potential to expand the limited therapeutic window of approved inhibitors and significantly improve ...

PLCB1 functions as an oncogenic driver in cholangiocarcinoma development that confers an actionable therapeutic vulnerability to AKT inhibition.

Synthetic lethality and mass spectrometry were used to identify novel metabolic vulnerabilities in cancers with IDH1, but not IDH2, mutations that are targetable in the setting of ivosidenib ...

GEN1046, which combines simultaneous PD-1/PD-L1 blockade and conditional 4-1BB stimulation, shows encouraging preclinical results and in a first-in-human dose-escalation study, demonstrates manageable ...

Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has critical implications ...

Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRAS G12D) being the most common. Here, we tested the ...